Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

Key Takeaways Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...

Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...